Author(s)

Ziren Wang

Corresponding Author

Ziren Wang

Abstract

Harnessing patient’s own immune system to fight against cancers is a permanent goal of tumor immunotherapy. Chimeric antigen receptor (CAR) T cell therapy is emerging as a promising way in treating leukemia and solid tumors. Now, two commercial CAR T therapies have been approved by the US Food and Drug Administration for treating patients with B cell lymphomas. However, continuous efforts are still need to increase the efficacy of CAR T cells in curing cancers, and especially to improve their activity in solid tumors. This review summarizes the novel design of CAR structure and many other measures in improving the anti-tumor activity and overcoming immunosuppressive tumor microenvironment, and reducing toxicities.

Keywords

CAR T, Tumor Immunotherapy, Anti-CD19, CAR Design